Therapeutic Translation of Epicardial Adipose Tissue Targeting in Heart Failure With Preserved Ejection Fraction: How Far Are We? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42500886
Exploring the role of epicardial adipose tissue in HFpEF, this study examines therapeutic strategies, despite current gaps in targeted treatment.
EAT expansion links to HFpEF development. Reducing EAT may improve prognosis, but specific treatments remain unavailable. Modulating inflammatory response and systemic energy metabolism are beneficial strategies.
Sustained Type 2 Diabetes Remission and Metabolic Health Through Intensive Lifestyle Intervention: A Case Report With a Nine-Year Follow-Up. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42460222
A whole-food, plant-based diet, exercise, and stress reduction contributed to a nine-year type 2 diabetes remission, highlighting potential cardiovascular benefits.
Intensive lifestyle intervention led to sustained type 2 diabetes remission and metabolic health improvement over nine years without medications, with potential cardiovascular benefits.
Ferroptosis in Doxorubicin-Induced Cardiotoxicity: From Molecular Mechanisms to Therapeutic Strategies and Clinical Management Paradigms. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42416573
Explore the role of ferroptosis in doxorubicin-induced cardiotoxicity and review potential therapeutic strategies targeting this pathway for cardiac management.
Ferroptosis is central in doxorubicin-induced cardiotoxicity, involving disrupted iron homeostasis and lipid peroxidation. Strategies include inhibiting GPX4, FSP1, and using cardiac-targeted nanodelivery systems.
Inclisiran Response in a Patient With Familial Hypercholesterolemia After Suboptimal Response to Evolocumab. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42397340
A patient with familial hypercholesterolemia responded well to inclisiran after an inadequate response to evolocumab, as detailed in this case report.
Inclisiran showed efficacy in reducing LDL cholesterol in a patient with familial hypercholesterolemia (Afrikaner-2 variant) after suboptimal response to evolocumab.
Biologics for cardiovascular diseases: from bench to bedside. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42366210
Explore the role of biologics, including gene therapies and lipid modulation, in managing cardiovascular diseases by addressing pathophysiological mechanisms.
Biologics offer potential for disease modification in cardiovascular medicine, focusing on cardiac regeneration, reverse remodeling, genetic correction, vascular modulation, and lipid metabolism.